114 related articles for article (PubMed ID: 8287204)
21. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases.
Perlemuter G; Cacoub P; Chaussade S; Wechsler B; Couturier D; Piette JC
Arthritis Rheum; 1999 Jul; 42(7):1545-9. PubMed ID: 10403284
[TBL] [Abstract][Full Text] [Related]
22. Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide.
Maeda I; Tsuneto S; Yasui Y; Ueda Y; Kimura T
J Pain Symptom Manage; 2014 Feb; 47(2):e2-5. PubMed ID: 24388125
[No Abstract] [Full Text] [Related]
23. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H
Minoura T; Takeuchi M; Morita T; Kawakami K
J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616
[TBL] [Abstract][Full Text] [Related]
24. Octreotide in malignant intestinal obstruction.
Pandha HS; Waxman J
Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
[TBL] [Abstract][Full Text] [Related]
25. Antisecretory agents in gastrointestinal obstruction.
Muir JC; von Gunten CF
Clin Geriatr Med; 2000 May; 16(2):327-34. PubMed ID: 10783431
[TBL] [Abstract][Full Text] [Related]
26. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
27. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
[TBL] [Abstract][Full Text] [Related]
28. The value of a systematic approach to malignant bowel obstruction.
Krouse RS
J Support Oncol; 2008 Mar; 6(3):116-7. PubMed ID: 18402302
[No Abstract] [Full Text] [Related]
29. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.
Shinjo T; Kagami R
Support Care Cancer; 2009 Jun; 17(6):753-5. PubMed ID: 19277723
[TBL] [Abstract][Full Text] [Related]
30. Malignant bowel obstruction: tailoring treatment to individual patients.
Ripamonti CI
J Support Oncol; 2008 Mar; 6(3):114-5. PubMed ID: 18402301
[No Abstract] [Full Text] [Related]
31. [Treatment with octreotide for functional obstructions in scleroderma].
Emmerich J; Roux ME; Capron L; Fiessinger JN
Presse Med; 1992 Feb; 21(7):316-7. PubMed ID: 1532651
[No Abstract] [Full Text] [Related]
32. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review.
Mercadante S; Casuccio A; Mangione S
J Pain Symptom Manage; 2007 Feb; 33(2):217-23. PubMed ID: 17280927
[TBL] [Abstract][Full Text] [Related]
33. Octreotide for malignant bowel obstruction: commentary on Currow et al.
Mercadante S
J Pain Symptom Manage; 2015 May; 49(5):813. PubMed ID: 25863013
[No Abstract] [Full Text] [Related]
34. Can malignant bowel obstruction in advanced cancer patients be treated at home?
Porzio G; Aielli F; Verna L; Galletti B; Shoja E Razavi G; Ficorella C
Support Care Cancer; 2011 Mar; 19(3):431-3. PubMed ID: 20872024
[TBL] [Abstract][Full Text] [Related]
35. Improvement in survival of mice with proximal small bowel obstruction treated with octreotide.
Gittes GK; Nelson MT; Debas HT; Mulvihill SJ
Am J Surg; 1992 Feb; 163(2):231-3. PubMed ID: 1739178
[TBL] [Abstract][Full Text] [Related]
36. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
Jatoi A; Podratz KC; Gill P; Hartmann LC
J Support Oncol; 2004; 2(4):323-34; discussion 334-7. PubMed ID: 15357517
[TBL] [Abstract][Full Text] [Related]
37. [Effects of octreotide on small bowel obstructions in rats].
Cho JH; Kang HG; Kim SH; Lee HS; Lee KR; Kang HY
Korean J Gastroenterol; 2003 Oct; 42(4):283-8. PubMed ID: 14634347
[TBL] [Abstract][Full Text] [Related]
38. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction.
Massacesi C; Galeazzi G
Palliat Med; 2006 Oct; 20(7):715-6. PubMed ID: 17060271
[TBL] [Abstract][Full Text] [Related]
39. Intestinal obstruction.
Baines MJ
Cancer Surv; 1994; 21():147-56. PubMed ID: 8564990
[TBL] [Abstract][Full Text] [Related]
40. Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction.
Zhang Y; Gao Y; Ma Q; Dang C; Wei W; De Antoni F; Rocci R; Chen W
Dig Liver Dis; 2006 Mar; 38(3):188-94. PubMed ID: 16311083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
